H. Lundbeck A.S. was established in 1915 with its headquarters at Copenhagen, Denmark. Lundbeck is the only totally incorporated pharmaceutical enterprise that is completely targeting to invent latest and effective therapies for central nervous system – CNS ailments. Such intentional targets permit the company to institute healthy associations with intellectuals, clinicians and patients having interests in the CNS ailments.

 

The company has introduced a couple of new drugs like CIPRALEX having Escitalopram as its key ingredient which is rather more selective serotonin reuptake inhibitor-SSRI used for treating depression, panic and anxiety related ailments as well as EBIXA made from Memantine which is the pioneering drug in the totally latest therapeutical category for treating rather harsh to acute Alzheimer’s disease.

 

Further during 2005, the company introduced another drug like AZILECT having Rasagiline which is used for treating the Parkinson’s disease. Maintaining the sequence, in the year 2006 the company re-introduced SERDOLECT drug made from Sertindole effectively used for treating Schizophrenia disorders.   

 

The company is indeed committed to R & D having the extensive track record of generating advanced CNS therapies with the help of modern R & D techniques. Several products of Citalopram like CIPRAMIL, SEROPRAM and CIPRAM have placed the company in the leading position amongst the European antidepressant markets.  

 

The company has its presence through its subsidiaries in 58 nations employing over 5,000 people all over the world. The company is serving the patients with its excellent range of products for various treatments that include depression, schizophrenia, Alzheimer’s and Parkinson’s diseases, sleep disorders and their base in the central nervous system making the prime sector of focusing.